Daix in France, and New York in the United States, March 23, 2026 – A biopharmaceutical company called Inventiva (IVA on Euronext Paris and NASDAQ) specializing in oral treatments for metabolic dysfunction-related steatohepatitis (MASH) revealed its plan to disclose the financial outcomes of 2025 on Monday, March 30, 2026, post the closing of the U.S. markets.